Mirabegron
Mirabegron
Mirabegron
| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-4228-10MG | Mirabegron | 10mg | $105.00 | |
| GBM-4228-50MG | Mirabegron | 50mg | $368.00 |
-
Description
beta-3 Adrenergic agonist
-
Specifications
Bioassays Specification Bio-Activity beta-3 Adrenergic agonist Chemical Name 2-(2-Amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide Function / Pharmacology Mirabegron is a potent (EC50 = 22.4 nM CHO cells expressing human ß3-ARs) beta-3 adrenergic receptor (ß3-AR) agonist with high selectivity over the beta-1 and beta-2 receptors.1 Clinically useful for the treatment of overactive bladder syndrome. Chronic treatment of human subjects with mirabegron increased brown adipose tissue (BAT) metabolic activity, increased HDL and bile acid levels, and produced substantial improvements in glucose and insulin metabolism.2 Mirabegron inhibited tumor growth in various tumor models including pancreatic ductal adenocarcinoma and hepatocellular carcinoma via altering global metabolism in an uncoupling protein 1 (UCP1; a key protein for non-shivering thermogenesis) dependent manner.3 CAS# 223673-61-8 MW 396.5 Molecular Formula C21H24N4O2S Solubility Soluble in DMSO (up to 40 mg/ml) Supplied powder Storage as supplied -20°C Ship temp Ambient References 1) Takasu et al. (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function; J. Pharmacol. Exp. Ther. 321 642 2) O’Mara et al. (2020) Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity; J. Clin. Invest. 130 2209 3) Sun et al. (2023) Mirabegron displays anticancer effects by globally browning adipose tissues; Nat. Commun. 14 7610 Antibody Specification Alternate Names YM178; (R)-2-(2-Aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide Protein Specification Purity >98% - Reviews
| Bioassays Specification | |
| Bio-Activity | beta-3 Adrenergic agonist |
| Chemical Name | 2-(2-Amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide |
| Function / Pharmacology | Mirabegron is a potent (EC50 = 22.4 nM CHO cells expressing human ß3-ARs) beta-3 adrenergic receptor (ß3-AR) agonist with high selectivity over the beta-1 and beta-2 receptors.1 Clinically useful for the treatment of overactive bladder syndrome. Chronic treatment of human subjects with mirabegron increased brown adipose tissue (BAT) metabolic activity, increased HDL and bile acid levels, and produced substantial improvements in glucose and insulin metabolism.2 Mirabegron inhibited tumor growth in various tumor models including pancreatic ductal adenocarcinoma and hepatocellular carcinoma via altering global metabolism in an uncoupling protein 1 (UCP1; a key protein for non-shivering thermogenesis) dependent manner.3 |
| CAS# | 223673-61-8 |
| MW | 396.5 |
| Molecular Formula | C21H24N4O2S |
| Solubility | Soluble in DMSO (up to 40 mg/ml) |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Takasu et al. (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function; J. Pharmacol. Exp. Ther. 321 642 2) O’Mara et al. (2020) Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity; J. Clin. Invest. 130 2209 3) Sun et al. (2023) Mirabegron displays anticancer effects by globally browning adipose tissues; Nat. Commun. 14 7610 |
| Antibody Specification | |
| Alternate Names | YM178; (R)-2-(2-Aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide |
| Protein Specification | |
| Purity | >98% |